The Nippon India Nifty Pharmabees ETF, commonly known as PHARMABEES, is an exchange-traded fund that aims to replicate the performance of the Nifty Pharma Index. This index comprises leading pharmaceutical companies in India, offering investors exposure to the country’s pharmaceutical sector.
Key Details:
- Inception Date: July 2, 2021.
- Fund Manager: Himanshu Mange.
- Expense Ratio: 0.21%.
- Benchmark Index: Nifty Pharma TRI.
Top Holdings:
As of October 31, 2024, the ETF’s top holdings include:
- Sun Pharmaceutical Industries Ltd: 24.69%
- Cipla Ltd: 10.83%
- Divi’s Laboratories Ltd: 10.06%
- Dr. Reddy’s Laboratories Ltd: 9.42%
- Lupin Ltd: 6.35%
Performance Overview:
The PHARMABEES ETF has demonstrated strong performance, closely tracking the Nifty Pharma Index. As of September 28, 2024, the fund’s returns were:
- 1-Year Return: 45.60%
- 3-Year Annualized Return: 15.32%
- Since Inception Annualized Return: 14.68%
These figures highlight the ETF’s consistent growth and alignment with the pharmaceutical sector’s performance.
What is the price of Pharma ETF?
As of December 23, 2024, the Net Asset Value (NAV) of the Nippon India Nifty Pharma ETF (PHARMABEES) is ₹23.01.
The ETF’s price can fluctuate during trading hours based on market conditions.
Which company is Pharmabees under?
The Pharmabees ETF is managed by Nippon India Mutual Fund. It tracks the Nifty Pharma Index, which includes leading pharmaceutical companies in India. Nippon India Mutual Fund, part of the Nippon Life Insurance Group (a Japanese financial services company), is one of the prominent asset management firms in India offering a range of investment products, debt, and hybrid funds.
Which company is Pharmabees under? with table
The Pharmabees ETF is managed by Nippon India Mutual Fund. Below is a table summarizing key details related to Pharmabees and its parent company:
| Category | Details |
| ETF Name | Pharmabees (Nippon India Nifty Pharma ETF) |
| Managed By | Nippon India Mutual Fund |
| Parent Company | Nippon Life Insurance Group (Japan) |
| Fund Type | Exchange Traded Fund (ETF) |
| Index Tracked | Nifty Pharma Index |
| Expense Ratio | 0.21% |
| Launch Date | July 2, 2021 |
Nippon India Mutual Fund is part of Nippon Life Insurance, a major Japanese financial institution.
Which Pharma ETF is best in India?
Here is a comparative table of some of the best Pharma-focused ETFs and mutual funds in India, helping you decide which one may be suitable for your investment goals:
| ETF/Fund Name | Type | Expense Ratio | Fund Size (AUM) | 5-Year Annualized Return | Benchmark Index | Focus |
| Nippon India Nifty Pharma ETF | ETF | 0.21% | ₹840.57 crore | Not available (Launched in 2021) | Nifty Pharma Index | Top pharmaceutical companies |
| ICICI Prudential Pharma Healthcare and Diagnostics (P.H.D) Fund | Mutual Fund | 1.13% | ₹5,045 crore | 21.79% | NA | Pharmaceuticals, healthcare, diagnostics |
| DSP Healthcare Fund | Mutual Fund | 1.27% | ₹3,249 crore | 32.5% | NA | Healthcare and pharma |
| SBI Healthcare Opportunities Fund | Mutual Fund | 1.18% | ₹3,460 crore | 25.16% | NA | Healthcare and pharma |
| Mirae Asset Healthcare Fund | Mutual Fund | 1.45% | ₹2,200 crore | 30.72% | NA | Healthcare and pharma |
Explanation:
(1) Nippon India Nifty Pharma ETF:
- Best for: Investors looking for ETF simplicity with lower expense ratios and exposure to a broad-based pharma index.
- Pros: Low expense ratio, direct tracking of Nifty Pharma Index.
- Cons: May not capture opportunities beyond the index.
(2) ICICI Prudential P.H.D Fund:
- Best for: Those looking to diversify within pharmaceuticals, healthcare, and diagnostics.
- Pros: Broader sectoral exposure, strong historical returns.
- Cons: Slightly higher expense ratio than ETFs.
(3) SBI Healthcare Opportunities Fund:
- Best for: Investors seeking a well-diversified pharma fund with solid historical returns.
- Pros: Good returns, large AUM indicates popularity.
- Cons: Higher expense ratio.
(4) Mirae Asset Healthcare Fund:
- Best for: Aggressive investors looking for high returns in healthcare.
- Pros: Competitive returns in the sector.
- Cons: High expense ratio.
Conclusion:
- If you prefer ETFs for lower costs and index-tracking, the Nippon India Nifty Pharma ETF is an excellent choice.
- For mutual funds, DSP Healthcare Fund and Mirae Asset Healthcare Fund stand out due to their strong returns, though they carry higher expense ratios.
Consider your risk appetite, investment horizon, and objectives before making a decision.
Nippon India ETF Nifty IT (ITBEES): A Complete Guide to Small-Cap Investments
HDFC NIFTY Smallcap 250 ETF: A Complete Guide to Small-Cap Investments For Beginners
Mirae Asset NYSE FANG+ ETF Review: A Guide to Investing in Global Tech Innovators
Disclaimer: The content on this website is intended for informational purposes only and should not be interpreted as financial or investment advice. Engaging in stock market activities involves inherent risks, and outcomes can be unpredictable. While we strive to provide accurate and up-to-date information, we do not make any guarantees regarding the completeness or reliability of the content. Any investment decisions you make should be based on your own research and consultation with a qualified financial professional. We are not responsible for any financial gains or losses resulting from actions taken based on the information provided here. Always invest wisely and at your own risk.
